Synergy Pharmaceuticals (SGYP) : Traders are bullish on Synergy Pharmaceuticals (SGYP) as it has outperformed the S&P 500 by a wide margin of 28.26% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.24%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.21% in the last 1 week, and is up 28.75% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Synergy Pharmaceuticals, Inc. is up 57.98% in the last 3-month period. Year-to-Date the stock performance stands at -9.17%. The stock has recorded a 20-day Moving Average of 14.43% and the 50-Day Moving Average is 26.21%.
Synergy Pharmaceuticals (NASDAQ:SGYP): The stock opened at $5.24 on Friday but the bulls could not build on the opening and the stock topped out at $5.24 for the day. The stock traded down to $5.10 during the day, due to lack of any buying support eventually closed down at $5.15 with a loss of -1.72% for the day. The stock had closed at $5.24 on the previous day. The total traded volume was 1,697,775 shares.
Also, Equity Analysts at the Brokerage Firm, Rodman & Renshaw, maintains their rating on the shares of Synergy Pharmaceuticals (NASDAQ:SGYP). Rodman & Renshaw has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $15 per share from a prior target of $16. The rating by the firm was issued on May 9, 2016.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.